Analyst Ratings for Alexion Pharmaceuticals (ALXN)
ALXN Rating Summary
ALXN Price Target Summary
- Highest: $132.00 (Canaccord Genuity)
- Lowest: $90.00 (Jefferies)
- Average: $111.79
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$111.79 (+22.7%)
Avg. $ Target:
$111.79 (+22.7%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/20/2013 | Lazard Capital | Upgrade | Buy (Neutral) |
N/A (N/A) |
83.39 | 91.09 | 9.23% | Details |
| 1/3/2013 | Janney Montgomery Scott | New Coverage | Neutral (N/A) |
107.00 (N/A) |
100.05 | 91.09 | -8.96% | Details |
| 12/13/2012 | Goldman Sachs | New Coverage | Buy (N/A) |
120.00 (N/A) |
95.09 | 91.09 | -4.21% | Details |
| 12/7/2012 | Citi | New Coverage | Neutral (N/A) |
104.00 (N/A) |
93.59 | 91.09 | -2.67% | Details |
| 11/9/2012 | Guggenheim | New Coverage | Buy (N/A) |
121.00 (N/A) |
88.69 | 91.09 | 2.71% | Details |
| 8/24/2012 | ThinkEquity | New Coverage | Hold (N/A) |
105.00 (N/A) |
103.70 | 91.09 | -12.16% | Details |
| 3/26/2012 | Canaccord Genuity » Updated 9/24/2012 |
New Coverage | Buy (N/A) |
132.00 (115.00) |
93.82 | 91.09 | -2.91% | Details |
| 2/23/2012 | UBS » Updated 4/26/2013 |
Upgrade | Buy (N/A) |
123.00 (120.00) |
83.46 | 91.09 | 9.14% | Details |
| 2/10/2012 | Baird » Updated 2/15/2013 |
Upgrade | Outperform (N/A) |
125.00 (N/A) |
80.41 | 91.09 | 13.28% | Details |
| 12/9/2011 | Barclays » Updated 9/14/2012 |
New Coverage | Overweight (N/A) |
120.00 (112.00) |
64.18 | 91.09 | 41.93% | Details |
| 10/4/2011 | JPMorgan » Updated 3/21/2012 |
New Coverage | Overweight (N/A) |
105.00 (N/A) |
60.87 | 91.09 | 49.65% | Details |
| 4/25/2011 | Needham & Company » Updated 7/22/2011 |
Downgrade | Hold (N/A) |
N/A (N/A) |
99.76 | 91.09 | -8.69% | Details |
| 4/11/2011 | Bernstein | Downgrade | Market Perform (N/A) |
N/A (N/A) |
102.38 | 91.09 | -11.03% | Details |
| 1/18/2011 | Gleacher & Co. | Upgrade | Buy (N/A) |
N/A (N/A) |
82.37 | 91.09 | 10.59% | Details |
| 12/10/2010 | Wells Fargo » Updated 4/25/2013 |
New Coverage | Market Perform (N/A) |
N/A (N/A) |
77.21 | 91.09 | 17.98% | Details |
